4D Molecular Therapeutics (4D Molecular Therapeutics) Debt-to-Equity : 0.05 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is 4D Molecular Therapeutics Debt-to-Equity?

4D Molecular Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.15 Mil. 4D Molecular Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11.52 Mil. 4D Molecular Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $307.83 Mil. 4D Molecular Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for 4D Molecular Therapeutics's Debt-to-Equity or its related term are showing as below:

FDMT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.05 Max: 0.07
Current: 0.05

During the past 7 years, the highest Debt-to-Equity Ratio of 4D Molecular Therapeutics was 0.07. The lowest was 0.05. And the median was 0.05.

FDMT's Debt-to-Equity is ranked better than
73.99% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs FDMT: 0.05

4D Molecular Therapeutics Debt-to-Equity Historical Data

The historical data trend for 4D Molecular Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4D Molecular Therapeutics Debt-to-Equity Chart

4D Molecular Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.05

0.07

0.05

4D Molecular Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.07	0.07	0.05	0.05	0.05

Competitive Comparison of 4D Molecular Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, 4D Molecular Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4D Molecular Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where 4D Molecular Therapeutics's Debt-to-Equity falls into.

4D Molecular Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

4D Molecular Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.149	+	11.522)	/	307.829
	=	0.05

4D Molecular Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.149	+	11.522)	/	307.829
	=	0.05

4D Molecular Therapeutics (NAS:FDMT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

4D Molecular Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of 4D Molecular Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

4D Molecular Therapeutics (4D Molecular Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4D Molecular Therapeutics Inc (NAS:FDMT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608

Website

https://www.4dmoleculartherapeutics.com

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.

Executives

David Kirn	director, officer: Chief Executive Officer	C/O 4D MOLECULAR THERAPEUTICS INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Uneek Mehra	officer: See Remarks	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Rose Sharon Shabet	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Illiquid Investments Sub-master Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Jacob Chacko	director	C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Scott Bizily	officer: Chief Legal and HR Officer	C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608
Robert Young Kim	officer: Chief Medical Officer	C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608
Noriyuki Kasahara	director	C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104